Ginkgo Bioworks (DNA) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 23.1% versus a loss of 29.5%. Over five years, LXRX leads with a -71.4% price change compared with -97.6% for DNA. Lexicon Pharmaceuticals is the larger company by market cap ($783.1 million vs $763.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | LXRX |
|---|---|---|
| Share price | $11.34 | $1.76 |
| Market cap | $763.64M | $783.12M |
| 1-day change | -1.13% | 0.00% |
| YTD return | +36.46% | +53.04% |
| 1-year return | -29.52% | +23.08% |
| 5-year return | -97.62% | -71.43% |
| EPS (TTM) | $-5.06 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $2.68 |
| 52-week low | $5.37 | $1.10 |
| Distance from 52-week high | -37.76% | -34.33% |
| Analyst consensus | none | buy |
| Avg. price target upside | -38.27% | +158.52% |
| Average volume | 1.80M | 2.90M |
| Shares outstanding | 55.38M | 444.96M |
| Employees | 485 | 81 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed DNA by 52.6 percentage points over the past year.
- The two companies sit in different sectors: Ginkgo Bioworks in Healthcare and Lexicon Pharmaceuticals in Health Care.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
DNA vs LXRX FAQ
Which is bigger, Ginkgo Bioworks or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $783.12M compared with $763.64M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or LXRX?
LXRX returned +23.08% over the past 12 months, compared with -29.52% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Lexicon Pharmaceuticals in the same industry?
No. Ginkgo Bioworks is in the Healthcare sector, while Lexicon Pharmaceuticals is in Health Care.